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Abstract
In this study, we developed a method for modeling the progression and detection of lung cancer based on the smoking
behavior at an individual level. The model allows obtaining the characteristics of lung cancer in a population at the time of
diagnosis. Lung cancer data from Surveillance, Epidemiology and End Results (SEER) database collected between 2004 and
2008 were used to fit the lung cancer progression and detection model. The fitted model combined with a smoking based
carcinogenesis model was used to predict the distribution of age, gender, tumor size, disease stage and smoking status at
diagnosis and the results were validated against independent data from the SEER database collected from 1988 to 1999. The
model accurately predicted the gender distribution and median age of LC patients of diagnosis, and reasonably predicted
the joint tumor size and disease stage distribution.
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Introduction
Lung cancer is one of the most deadly diseases worldwide,
largely because most patients present with advanced-stage disease
at the time of diagnosis [1,2]. Most patients have clinical stage III
or IV disease when they first notice symptoms and seek medical
attention, which results in a poor prognosis. Age, gender, smoking
status, tumor size, and disease stage at the time of diagnosis are
highly related to the prognosis of patients with lung cancer [3,4,5].
In this article, we use mathematical methods to disentangle the
tumorigenesis and detection processes. The goal of this model is to
trace the timeline of an individual from his/her birth to the time of
lung cancer initiation, progression, detection, and death. Thus, we
combined models of carcinogenesis (cancer development until the
first malignant cell), tumor progression (growth and metastasis),
and detection, to construct a framework for modeling lung cancer
at an individual level. Using this framework, we could infer
characteristics that cannot be observed in clinical practice,
including age of the patient when the primary tumor and nodal
and distant metastases are formed. We were also able to evaluate
characteristics that can only be partially observed, such as the
tumor growth rate, and closely reconstruct characteristics that can
be observed clinically, notably, tumor size and disease stage at the
time of diagnosis. This procedure may be useful for better
understanding the formation of the current lung cancer patient
population and characterization of the future lung cancer trends
with changes in smoking behavior and detection methods.
Materials and Methods
1. Lung cancer patients identified in the Surveillance,
Epidemiology and End Results (SEER) database
Age, sex, disease stage, and tumor size for lung cancer patients
who were diagnosed between 1973 and 2008 are available in the
SEER database [6]. For patients diagnosed from 1988 to 1999, we
used information on tumor size, with staging determined
according to SEER extent of disease codes, which categorize
tumors as localized, regional, and distant. For patients diagnosed
from 2004 to 2008, the staging system developed by the American
Joint Committee on Cancer was used to obtain tumor size and
tumor node metastasis (TNM) disease stage information. Tumor
size was measured as the maximum diameter, and we calculated
the volume according to an assumption that a tumor grows as a
sphere. We re-categorized the tumors into groups from 0 to 20 cm
(with 1-cm increments) according to their maximum diameter.
2. Carcinogenesis modeling
For the carcinogenesis model, we used the two-stage clonal
expansion (TSCE) model developed by Moolgavkar and Venzon
[7] to calculate the age of the patient at tumor initiation. This
model leads to an explicit formula for the distribution of the total
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duration, T, of the first two stages in the carcinogenesis process
(the transitions from normal to initiated cell and initiated to
malignant cell), which encompasses the time from the birth of an
individual to the onset of malignancy [8]. A smoking-based
modification of the TSCE model relating smoking intensity
measured in packs per day (ppd) to the parameters of the TSCE
model through response functions (with the parameters n0, a0, c0,
a1, and a2, as listed in File S1) was chosen. Smoking duration was
incorporated to produce a more specific Survival function of the
age at tumor initiation for individual never, current and former
smokers.[9,10,11].
The smoking history generator (SHG, version 5.2.1) [12]from
the Cancer Intervention and Surveillance Modeling Network
(CISNET), which produced smoking duration and intensity data
for individuals, was incorporated into the smoking-based TSCE
model by using the parameters listed in Table S1. Parameters for
males and females were estimated using the data from Cancer
Prevention Study I (CPS-I) and from Nurses’ Health Study (NHS),
respectively. The SHG was also used to generate an age of death
due to causes other than lung cancer.
3. Tumor growth and metastasis modeling
For the tumor growth and metastasis models, we assumed that
the hazard of tumor progression is based on the activity of the
tumor cells, and tumor cells detach from the primary tumor and
transfer to another part of the body, leading to metastases [13]
3.1. Assumptions. The following assumptions were made in
modeling tumor growth and metastasis:
1) The primary tumor grows from a single cell, with an assumed
volume of 161029 cm3 [14]. The growth rate l, which is
related to the tumor doubling time by the expression
DT~Ln2=l, is determined at the time of tumor initiation
and is assumed to remain the same over time.
2) The growth rate follows a gamma distribution, with shape and
scale parameters h and K.
3) All metastases are derived from the primary tumor, which
means cells detach from the primary tumor at the rate j and
are transferred and deposited at the rate m at a new metastasis
site [13]. We don’t consider secondary metastasis from
existing metastasis.
4) The activity of the tumor cell is related to how fast the tumor
grows and how easily the cells detach. Specifically, the faster
the primary tumor grows, the easier it is for the cells to detach.
We define the tumor cell’s activity a, to which the growth rate
l is proportional, l= e16a (where e1 is a constant). The cell-
detachment rate, b, is also proportional to a, b= e26a (where
e2 is another constant). Thus, b~
e2
e1
l, where
e2
e1
~j is a
parameter representing the relationship between b and l. If
the tumor with volume S grows exponentially, S~elt , the
total number of detached cells before time t0 is e
jlt0~Sj0 ; we
assume 0vjv1, the interpretation of which is that cells
always detach from the primary tumor but not all tumor cells
will detach.
5) The detached cells will be transferred and deposited at new
locations. The aggregate rate of transfer and deposition is m. m
could be a constant parameter or a functional parameter
determined by a biological process, such as the rate of
synthesis of proteins that help transfer the tumor cells across
the blood vessel wall [13].
6) Metastases are defined as either nodal or distant. We assume a
different rate m (mn and mm) for each type of metastasis, mn for
nodal and mm for distant metastasis. We also assume that the
detached cells can move to nodal sites at least as easily as to
distant sites (mn$mm).
7) The hazard function for metastasis (nodal or distant) is related
to the number of tumor cells that have detached from the
primary tumor and have been successfully transferred and
deposited at nodal or distant locations. Assuming exponential
growth, the hazard functions for nodal and distant metastases
are hn~mn|S
j and hm~mm|S
j, respectively. The cumu-
lative distribution functions (c.d.f.) are defined below:
Fn sð Þ~1{e
{
ÐS
0
hn sð Þds
~1{e
{
mn
jz1
S jz1ð Þ
Fm sð Þ~1{e
{
ÐS
0
hm sð Þds
~1{e
{
mm
jz1
S jz1ð Þ
with the tail functions (or survival functions) Fn, Fm. If j~0, we
assume no cells detach from the primary tumor, mn~0 and mm~0.
1) Assumption mn$mm implies that Fn sð Þ§Fm sð Þ, where Fn(s)
and Fm(s) are corresponding cumulative distribution functions
defined above. Primary tumor sizes at the time of initiation for
nodal and distant metastases, respectively, are denoted sni and
smi.
2) We assume that the cell’s activity changes after detachment
from the tumor, transfer and deposition at the metastatic site.
Cell at the nodal and distant metastatic sites grow three (3l) or
four (4l) times faster than the primary tumor [13,15,16],
correspondingly.
The primary tumor size is calculated using the tumor growth
model by giving the growing time t, with a constant growth rate l.
Thus, we rewrite Fn sð Þ,Fm sð Þ to Fn t,lð Þ~
Ðt
0
fn t,lð Þdt and
Fm t,lð Þ~
Ðt
0
fm t,lð Þdt, where fn t,lð Þ and fm t,lð Þ are the proba-
bility density functions (p.d.f.) of time that nodal and distant
metastases happened in a group of patients with the same tumor
growth rate l. Then,
fn tð Þ~
ð
fn t,lð Þ  c ljk,hð Þdl ; fm tð Þ
~
ð
fm t,lð Þ  c ljk,hð Þdl
where fn and fm are the p.d.f. of time that nodal and distant
metastases occurred in patients with tumor growth rate having a
Gamma distribution, and c is the Gamma distribution function
with parameters k and h. Then,
fn1m0 tð Þ~
ð
fn t,lð Þ{fm t,lð Þð Þ  c ljk,hð Þdl
where fn1m0 tð Þ is the p.d.f. of time for patients who had only nodal
metastases (without distant metastases) in the whole time period.
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4. Cancer detection modeling
To model cancer detection, we introduced a competing process
of detecting the disease through the primary tumor or nodal or
distant metastases, adapting the framework developed by Kimmel
and Flehinger. [17]
4.1. Assumptions. The following assumptions were made in
modeling cancer detection:
1) The detection of cancer is based on the detection method
used. The hazard of detection has a linear relationship with
tumor size. It also depends on the reasons (e.g., symptoms or
results of a screening test) that prompted the patient to seek
medical attention. For details, see equations (*) for hDp, hDn,
and hDm further on.
2) The detection of cancer is considered a competing process of
detecting the primary tumor or nodal or distant metastases.
The specific, mode-dependent hazard functions for the
detection through the primary tumor and nodal and distant
metastases are denoted as hDp, hDn, and hDm respectively (*).
Then the c.d.f. of the detection of primary tumors and nodal
and distant metastases are denoted as Dp(s), Dn(s), and Dm(s),
(**) with tail functions Dp sð Þ, Dn sð Þ,Dm sð Þ, respectively (for
details see equations (**)).
3) We also define primary tumor-size dependent hazard
functions for detection (irrespective of the mode of detection,
whether through the primary tumor, nodal metastases, or
distant metastases), z00(s), z10(s), z01(s), and z11(s), where z00(s)
is the hazard function for detecting, at size s, a cancer with no
detectable metastases; z10(s) is the hazard of detecting, through
whatever means, a cancer with the primary tumor of size s
and with detectable nodal but not distant metastases; likewise,
z01(s) is the hazard function for detecting, at size s, a cancer
with detectable distant but not nodal metastases; and z11(s) is
the hazard function for detecting, at size s, a cancer with
detectable nodal and distant metastases. Associated with these
hazard functions are the c.d.f. Znm(s) before they reach size S,
with tails Znm sð Þ, where n, m=0,1.
4) The observable variables in the study of size-dependent
metastases are sizes S of the primary tumor at detection and
the indicators N and M, where N, M=1/0 if nodal or distant
metastases are present/absent.
The relationship between assumptions (2) and (3) for the
detection model is shown in the following functions.
Z00~Dp
Z10~(Dp|Dn)\(Dp\Dn)~Dp7Dn
Z01~(Dp|Dm)\ Dp\Dm
 
~Dp7Dm
Z11~ Dp|Dn|Dm\Dp\Dn\Dp\Dm\Dm\Dn
 
|
(Dp\Dn\Dm)
To give the explicit expressions for Znm, the detailed expressions of
Dp,Dn and Dmare required. According to the assumptions of
metastases model, we know that:
Prfs0[SjN~0,M~0g~1{Fn sð Þ{Fm sð ÞzFn sð Þ\Fm sð Þ
¼D 1{Fn sð Þ
Prfs0[SjN~1,M~0g~Fn sð Þ{Fn sð Þ\Fm sð Þ ¼D Fn sð Þ{Fm sð Þ
Prfs0[SjN~0,M~1g~Fm sð Þ{Fn sð Þ\Fm sð Þ ¼D 0
Prfs0[SjN~1,M~1g~Fn sð Þ\Fm sð Þ ¼D Fm sð Þ
Where 0,S0#S, is the size of the primary tumor that was not
observed and D is considered the assumption that Fn sð Þ§Fm sð Þ.
Prfs0[SjN,Mg represented the probability of a primary tumor
with (1) or without (0) nodal (N) or distant (M) metastasis.
The joint density/ probability functions p s,n,mð Þ of random
variable S, N and M are presented below.
p s,0,0ð Þ~Z000 1{Fnð Þ
p s,1,0ð Þ~Z010 Fn{Fmð Þ
p s,0,1ð Þ~Z001|0~0
p s,1,1ð Þ~Z011Fm
Where Z0nm are probability density functions for detection.
The tumor-size dependent probability that nodal and distant
metastases are present at diagnosis, Wn sð Þ~PrfN~1js~Sg and
Wm sð Þ~PrfM~1js~Sg, respectively, where
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Wn sð Þ~ p s,1,0ð Þzp s,1,1ð Þ
p s,0,0ð Þzp s,1,0ð Þzp s,0,1ð Þzp s,1,1ð Þ
Wm sð Þ~ p s,0,1ð Þzp s,1,1ð Þ
p s,0,0ð Þzp s,1,0ð Þzp s,0,1ð Þzp s,1,1ð Þ
Substitute p s,n,mð Þ with Z0nm, Fn, and Fm we obtain:
Fn sð Þ~ WmZ
0
00Z
0
10z(Wn{Wm)Z
0
00Z
0
11
Z011Z
0
10zWn(Z
0
00{Z
0
10)Z
0
11zWm(Z
0
10{Z
0
11)Z
0
00
Fm sð Þ~ WmZ
0
00Z
0
10
Z011Z
0
10zWn(Z
0
00{Z
0
10)Z
0
11zWm(Z
0
10{Z
0
11)Z
0
00
5. Estimation
Methods provided by Kimmel and Flehinger [17] could be used
to estimate Wn, Wm, and Znm non-parametrically. We can also
estimate Dp,Dn,Dm,Fn, and Fm parametrically once the paramet-
ric tumor-growth and detection models are determined. Below we
provide an example.
Assuming that a tumor grows exponentially with a growth rate
l, and the metastases model described above, we have
Fn sð Þ~1{e
{
Ðs
0
hn uð Þdu
~1{e
{
mn
jz1
S jz1ð Þ
Fm sð Þ~1{e
{
Ðs
0
hm uð Þdu
~1{e
{
mm
jz1
S jz1ð Þ
Assuming that the hazard of tumor detection depends linearly on
the size of the tumor, denoting the efficiency of the detection by
tumor size as a and stage-dependent offset parameters as w0, w1
and w2, we obtain
hDp~aspzw0; ð Þ hDn~asnzw1; ð Þ hDm~asmzw2; ð Þ
Correspondingly
Dp sp
 
~1{e
{
Ðsp
0
hDp sð Þds
~1{e
{a
2
s2p{w0sp ðÞ
Dn snð Þ~1{e
{
Ðsn
0
hDn sð Þds
~1{e
{a
2
s2n{w1sn ðÞ
Dm smð Þ~1{e
{
Ðsm
0
hDm sð Þds
~1{e
{a
2
s2m{w2sm ðÞ
are c.d.f. of detection by size sp or sn or smof the primary tumor
and nodal and distant metastases. The primary tumor size when
the nodal and distant metastases arise is denoted as sni,smi. We can
then rewrite Dn sð Þ, Dm sð Þ as
Dn sð Þ~1{e{
a
2
(s{sni)
2{w1(s{sni), s§sni; Dn sð Þ~0,svsni
Dm sð Þ~1{e{
a
2
(s{smi)
2{w2(s{smi), s§smi ;Dm sð Þ~0,svsmi
where sni,smi are distributed with c.d.f. Fn .ð Þ,Fm .ð Þ, respectively,
and sniƒsmi.
5.1. Simulation-based estimation. The tumor growth and
metastasis model includes nine parameters (j, mn, mm, l K ,hð Þ, a,
W0, W1, W2). The joint likelihood function is difficult to maximize
directly. However, the tumor-growth, metastasis, and detection
models can be estimated separately, once multiple data points
for tumor size and disease stage are available. Another
method is to derive the least-squares function:
F G(xjj,mn,mm,k,h,a,W0,W1,W2ð Þ{Y^ xð ÞÞ, where g is the simu-
lated joint distribution of tumor size and stage and Y^ is the
observed joint distribution, based on these parameters, and apply
Figure 1. Probability density functions of nodal and distant
metastases from the time of tumor onset, using the estimated
parameters j=0.01, mn =8.05610
29, mm =2.78610
29, K =3.80
and h=1.15.
doi:10.1371/journal.pone.0093430.g001
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the Nelder-Mead method [18,19,20] to achieve the best fitted
parameters in the model. We used the second approach because
we did not have the multiple tumor-size measurements for
individuals to estimate the models separately.
F~
X2
i~0
X20
j~0
gij j,mn,mm,k,h,a,W0,W1,W2ð Þ{y^ij
 2
is the least square function where i is the stage status defined as
local (i=0, no nodal or distant metastasis N0M0), nodal (i=1,
nodal metastases but no distant metastases, N1M0), or distant
(i=2, M1), j is the number of tumor size group; gij() is the
simulated percentage of lung cancer with tumor in the size range
of j group and i stage among all detected lung cancer; y^ij is the
observed percentage of lung cancer with tumor in the size range of
j group and i stage among all detected lung cancer. Detailed
simulation procedure was in File S1.
We estimated the nine parameters (j, mn, mm, l K ,hð Þ, g, W0,
W1, W2) using the TNM staging data in the SEER database from
2004 to 2008 for model fitting. Since SHG is using year 2000 as a
cut-off point for the vital status observation, the joint distributions
of tumor size and disease stage from 1995 to 1999 were chosen as
the output of the simulation. The results were validated against
independent data from the SEER database collected from 1988 to
1999. These years were chosen as closest possible to 2004–2008
periods.
To simulate the LC population, we firstly used the smoking
history generator (SHG) to generate the underlying population.
We assumed that the number of persons before year 1890 was zero
and at the year of 1890 there were 2877000 new born babies (the
number of live births in each year was shown in the Figure S1). We
provided the year of birth (say 1890) and gender (half and half) to
SHG as inputs and repeated the SHG for 287700 times. Then we
got these persons’ basic information, including the year of death
(converted from the age of death, Ad, generated by SHG) and their
smoking history information. We then applied our simulation
strategy (described in the File S1 at section 2.1 simulation process)
to get LC candidates and the information of their tumor
progression. For the next year (say 1891), we added new born
babies to the underlying population and removed the persons that
were dead in the previous year (say 1890) from the population,
whenever she or he was LCs or ‘‘normal’’ persons. Thus, we had
underlying population, which would be approaching the real U.S.
population (figure S2), and the LC candidate population, which
were considered as an unperturbed (existing before detection) LC
population. Assuming that no LC-related death occurred before
detection, the yearly LC population would be achieved by
applying the detection model to the unperturbed LC population.
Results
Figure 1 shows the probabilities of nodal metastases and distant
metastases by the time from the tumor onset. The estimated
parameters j, mn, mm, k and h in Table 1, which gives the estimates
of the model parameters, were used to draw fn tð Þ, fm tð Þ and
fn1m0 tð Þ. These probability density functions showed that the
probability of nodal and distant metastasis began to fast increase at
2.5 years (about 900 days) and 3 years (about 1100 days) from the
time of tumor onset, respectively. It reached the highest at 6.4
years (about 2350 days) and 6.8 years (about 2500 days) from the
time of tumor onset.
1. Model Fitting
Figure 2 compares the characteristics of the population for the
years 1995–1999 generated by the fitted model to the SEER data
(2004–2008). For tumors smaller than 10 cm in diameter, the
proportion of N0M0-stage disease (no nodal or distant metastases)
more closely reproduces the SEER data (2004–2008). The
proportions of NxM0- and M1-stage disease are not reproduced
as accurately as the proportions of N0M0-stage disease, especially
when the tumors are larger than 5 cm in diameter. For tumors
smaller than 1 cm, the model predicted that about 50% and 35%
would be staged as N0M0 and M1, respectively, whereas the
actual percentages were 42% and 42% respectively.
2. Predicting Clinically Observable Characteristics
The fitted model was also validated by predicting the
characteristics of lung cancer patient population in United States
between 1988 and 1999. The model predicts both the gender
distribution among LC patients and median age that are quite
close to the 1988–1999 SEER data (Table 2).
Comparing the model prediction and the data, a smaller
proportion of patients was diagnosed with localized disease than it
was predicted (Figure 2c). One of the reasons may be the different
staging definitions used. The predicted tumor size distributions
were closer to the 2004–2008 SEER than to the 1988–1999 SEER
data (Figure 3 (a–c)).
Table 1. The estimates of model parameters, with asymptotic confidence intervals.
Parameter Description Estimate 95% CI
j Detachment rate 0.01 [0.008, 0.011]
mn Transfer and deposition rate of cells to nodal metastases 8.05610
29 [7.8061029, 8.2161029]
mm Transfer and deposition rate of cells to distant metastases 2.78610
29 [2.1561029, 3.3461029]
*K Shape parameter of gamma distribution of tumor growth rate 3.80 [3.77, 3.82]
*h Scale parameter of gamma distribution of tumor growth rate 1.15 [1.12, 1.19]
g Efficiency of the detection by tumor size 1.061024 [1.061025, 1.061023]
W0 Offset parameter for detection by N0M0 stage symptoms 0.065 [0.056, 0.075]
W1 Offset parameter for detection by N1M0 stage symptoms 1.50610
3 [1.306103, 1.806103]
W2 Offset parameter for detection by M1 Stage symptoms 7.00610
4 [6.506103, 8.006105]
*Assuming exponential tumor growth and the estimates of K and h, the average tumor growth rate E(l) corresponds to a doubling time of 55 to 60 days.
doi:10.1371/journal.pone.0093430.t001
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3. Predicting Clinically Unobservable Characteristics
Table 3 summarizes the predicted but not directly clinically
observable characteristics of the detected tumors. The mean time
from the tumor onset (when the first malignant cell appears) to
nodal and distant metastases (when they are just formed and not
yet observed) and diagnosis is about 4.77, 5.05, and 6.27 years,
respectively. The average size of the primary tumors when nodal
and distant metastases form was 0.09 cm3 and 0.24 cm3,
respectively. The median age at the time of tumor onset is 63
and the average growth rate corresponds to the tumor-volume
doubling time of about 60 days.
Table S2 shows the distribution of doubling time by tumor size
and stage. In clinical practice, a primary tumor with distant
metastases is more likely to be found with a smaller size than a
primary with no or only nodal metastases. This leads to an
observation that a primary tumor with distant metastases grows
slower and remains smaller. This Table also demonstrates that
faster growing tumors tend to be detected at larger sizes.
Discussion
The parameters estimated from the joint distribution of tumor
size and stage in the SEER database from 2004 to 2008 (Table 1)
were applied to generate a lung cancer patient population from
1988 to 1999 and validated by comparison of the results to the
data from the SEER database from 1988 to 1999. The model
accurately predicts the gender distribution and the median age of
lung cancer patients, and approximates the joint tumor size and
disease stage distribution. The accurate prediction of gender
distribution and age at diagnosis for 1988–1999 is largely owing to
the accuracy of the smoking-based TSCE model and SHG.
Because smoking behavior has changed significantly over the
recent decades, the output is sensitive to the year at detection,
which is why we are not able to reconstruct gender and age at
diagnosis in the SEER data from 2004 to 2008 as accurately. This
model overestimates the proportion of patients with tumors larger
than 10 cm in diameter and underestimates the proportion of
patients with tumors between 4 and 9 cm. These discrepancies are
more obvious for the distributions of the primary tumor size at
stages NxM0 and M1 than at N0M0. The reason might be that
the detection interval is fixed to 1 year in our model, whereas
patients may visit a doctor more frequently when symptoms
appear. For tumors smaller than 1 cm, the model underestimated
the proportion of patients with distant metastases.
We also used the fitted model to predict disease characteristics
that are difficult or impossible to observe in clinical practice.
According to the estimates of k and h in Table 1, the average
tumor growth rate, l, is about 4.4, which corresponds to a tumor-
volume doubling time of approximately 55 to 65 days given the
Figure 2. Comparison of the model fit in the period of 1995–1999 to the data of SEER 2004–2008. (a) the stage distribution conditional
on tumor size and (b) the tumor size distribution; (c) Comparison of the predictive model 1988–1999 and SEER 1988–1999, where the data is
summarized as stage distribution conditional on tumor size.
doi:10.1371/journal.pone.0093430.g002
Table 2. Comparison of the lung cancer patient population predicted by our model (1988 to 1999) with data from the SEER
database (from 1988 to 1999 and from 2004 to 2008).
Characteristics Prediction 1988 to 1999 (N=1,434,024) SEER 1988 to 1999 (N=184,952) SEER 2004 to 2008 (N=84,422)
Sex, n (%)
Male 833,754 (58.1) 108,205 (58.5) 44,228 (52.4)
Female 600,270 (41.9) 76,747 (41.5) 40,194 (47.6)
Age
Mean(SD) 67.31(14.26) 68.06(10.98) 69.75 (11.57)
Median 69 69 71
*Stage, n (%)
N0,M0 380,017 (26.5) 31,432 (17.0)(19.3)£ 20,863 (24.7)(28.1)£
Nx,M0 321,221 (22.4) 46,934 (25.4)(28.8)£ 17,889 (21.2)(24.1)£
M1 732,786 (51.1) 84,519 (45.7)(51.9)£ 35,357 (41.9)(47.7)£
Missing stage 0 (0) 22,067 (11.9) 10,313 (12.2)
Tumor Size, cm (Diameter)
Mean 4.57 4.30 4.21
Median 3.69 3.80 3.50
Std. deviation 3.21 3.03 3.11
Variance 10.33 9.20 9.65
Smoking Status, n (%)
Never 185,885 (13.0) ** -
Former 461,321 (32.2) - -
Current 786,818 (54.9) - -
*TNM staging being unavailable in SEER before 2004, we categorized tumors as localized, regional, and distant, for patients between 1988 and 1999.
**Smoking status is not reported in SEER.
£Excluding missing stage.
doi:10.1371/journal.pone.0093430.t002
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Figure 3. Tumor size distribution in predictive models, (a) Stage N0,M0 in SEER (2004–2008) and model (1988–1999), stage
Localized by SEER standard in SEER (1988–1999), (b) Stage Nx,M0 (x$1) in SEER (2004–2008) and model (1988–1999), stage
Regional by SEER standard in SEER (1988–1999), (c) Stage M1 in SEER (2004–2008) and model (1988–1999), stage Distant by SEER
standard in SEER (1988–1999).
doi:10.1371/journal.pone.0093430.g003
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exponential tumor growth model. This growth rate is higher than
what has been reported from screening studies [21,22,23], and
thus the difference is not entirely unexpected [24]. Besides,
introducing a time-dependent or size-dependent growth rate to the
tumor growth model may improve the fit of the model to the data.
The hazards for detection once nodal or distant metastases are
present are much larger than the hazards for detection when only
the primary tumor is present (W1, W2..W0), which reflects the
reality of disease detection in clinical practice. The mean duration
from tumor onset to detection was about 6 years in our model,
which is consistent with other disease progression models [25].
Among the detected tumors, the average primary tumor size at the
time of metastasis (nodal or distant) was less than 1 cm in
diameter, which is considerably smaller than that implied by other
predictions originating from screening data [17,26,27,28]. As-
sumptions regarding detection used in the models led to this
difference. In our model, the chances of detecting lung cancer
increase after nodal and distant metastases occur, and the
competitive detection model allows for the detection of the
metastasized tumor. This detection model does not require either
of the two extreme assumptions used in the previous studies
[8,9,17]: (1) that the probability to detect cancer is unchanged
when metastases are present, or (2) cancers are detected
immediately when metastatic spread occurs. To reduce the
complexity of the disease stage progression model, we did not
consider the possibility of a secondary spread of the disease from
nodal metastases. This may be the reason that the model did not as
accurately reproduce the proportion of nodal and distant
metastases as it did the proportion of localized tumors for tumor
sizes larger than 5 cm.
Our framework combines a carcinogenesis model with a model of
the natural history of tumor growth and progression, and a
detection model, to predict features of a lung cancer patient
population. This modular structure allows testing of different
detection strategies. One limitation of this model is that we were not
able to construct the overall likelihood function for the model in the
analytical form, and the Nelder-Mead estimation procedure used to
optimize the least square fit is time consuming. Another limitation is
that this framework largely depends on the smoking information
generated by the SHG, which has to be updated before it can be
used to accurately predict properties of future lung cancer patient
populations. We did not perform simulation by histology, which is
another limitation. Moreover, the model did not consider the
difference between the lung cancer risks in CPSI/NHS and SEER,
while the previously estimation of parameters in carcinogenesis
model was directly used. We cannot recalibrate carcinogenesis
model since no smoking information was recorded in SEER.
Conclusion
We proposed a model for predicting the natural disease
progression and detection of lung cancer that relies on the
following biologically and clinically reasonable assumptions: the
hazard function of tumor progression is based on the activity of the
tumor cells, which detach from the primary tumor and transfer to
another part of the body, leading to metastases [13]. Thus, the
metastasis process is related to the size of the primary tumor and
the tumor growth rate (which is also related to the activity of the
tumor cells). The detection of lung cancer in patients occurs as a
result of competing detection of the primary tumor or nodal or
distant metastasis. We used a TSCE model combined with the
smoking history generator to reproduce the population with
incipient tumors according to the yearly live birth number in the
United States (Figure S1). We then applied our models of the
tumor natural progression and its detection to re-create the lung
cancer patient population at the time of diagnosis. Lung cancer
data from SEER database collected between 2004 and 2008 were
used to fit the lung cancer progression and detection model. The
fitted model combined with a carcinogenesis model was used to
reconstruct the distribution of age, gender, tumor size, and disease
stage at diagnosis, and the results showed that the model
accurately predicted gender and median age, and reasonably
predicted the tumor size and disease stage distribution against
independent data from the SEER database collected from 1988 to
1999. This model framework provides a platform for estimating
the outcome of a strategy for the secondary prevention of lung
cancer before it is applied in clinic.
Supporting Information
Figure S1 Yearly live birth number in US used in the
simulation. For years in which the number of live births was
missing (between 1890 and 1908) we used the average number of
live births between 1909 and 1928 (2,877,000).
(TIF)
Figure S2 Comparison of U.S. population between
simulated data and Census Bureau data; the simulated
population deviates from the reality population after
year 1984, since SHG could not generate new babies
after 1984. However, we expect only minor if any effect of that
on the LC population, as lung cancer is very rare in young
individuals.
(TIF)
Table S1 Parameters of the response functions used in
the TSCE model [10].
(DOCX)
Table 3. Variables not directly observable for the detected
tumors in the predicted lung cancer population (1988–1999).
Variables not directly observable Mean (SD) Median (IQR)
Time from the tumor onset, (years)
To nodal metastasis 4.77 (2.70) 4.00 (3.00–6.00)
To distant metastasis 5.05 (2.86) 4.00 (3.00–6.00)
To diagnosis 6.27 (3.22) 5.00 (4.00–7.00)
Tumor volume (cm3) at metastasis
Sn 0.09 (8.4E-5) 0. 06 (0.03–0.13)
Sm 0.24(2.8E-4) 0.16 (0.07–0.33)
The linear tumor dimension (cm) at
metastasis
Dn 0.50 (1.7E-4) 0.49 (0.36–0.62)
Dm 0.68 (2.8E-4) 0.67 (0.50–0.85)
*Yearly Growth Rate l by stage
N0M0 6.17 (2.91) 6.30 (3.70–8.15)
N1M0 5.61 (1.68) 5.43 (4.45–6.71)
M1 3.79 (1.55) 3.54 (2.64–4.81)
*Doubling time by stage, (days)
N0M0 57.15 (43.83) 40.15 (31.02–68.41)
N1M0 49.40 (16.77) 46.52 (37.73–56.88)
M1 80.01 (38.66) 71.48 (52.65–95.69)
IQR, interquartile range; SD, standard deviation;* Here is the yearly growth rate
and doubling time of primary tumor.
doi:10.1371/journal.pone.0093430.t003
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Table S2 Doubling time by stages and tumor size for
the simulated LC population.
(DOCX)
File S1 Supporting text.
(DOCX)
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